Paugh Steven W, Payne Shawn G, Barbour Suzanne E, Milstien Sheldon, Spiegel Sarah
Department of Biochemistry, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
FEBS Lett. 2003 Nov 6;554(1-2):189-93. doi: 10.1016/s0014-5793(03)01168-2.
The potent immunosuppressive drug FTY720, a sphingosine analog, induces redistribution of lymphocytes from circulation to secondary lymphoid tissues. FTY720 is phosphorylated in vivo and functions as an agonist for four G-protein-coupled sphingosine-1-phosphate receptors. The identity of the kinase that phosphorylates FTY720 is still not known. Here we report that although both sphingosine kinase type 1 (SphK1) and type 2 (SphK2) can phosphorylate FTY720 with low efficiency, SphK2 is much more effective than SphK1. FTY720 inhibited phosphorylation of sphingosine catalyzed by SphK2 to a greater extent than it inhibits SphK1. Thus, SphK2 may be the relevant enzyme that is responsible for in vivo phosphorylation of FTY720.
强效免疫抑制药物FTY720是一种鞘氨醇类似物,可诱导淋巴细胞从循环系统重新分布至二级淋巴组织。FTY720在体内被磷酸化,并作为四种G蛋白偶联鞘氨醇-1-磷酸受体的激动剂发挥作用。使FTY720磷酸化的激酶的身份仍不清楚。在此我们报告,虽然1型鞘氨醇激酶(SphK1)和2型鞘氨醇激酶(SphK2)都能低效地使FTY720磷酸化,但SphK2比SphK1有效得多。FTY720对SphK2催化的鞘氨醇磷酸化的抑制程度大于对SphK1的抑制。因此,SphK2可能是负责FTY720体内磷酸化的相关酶。